Valeritas (NSDQ:VLRX) shares jumped this morning after the company touted positive results from its Enable study, showing that patients who switched from insulin pens and syringes to the company’s wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose.
The company presented three posters at this year’s meeting of the American Diabetes Association in Orlando, Florida.
Get the full story at our sister site, Drug Delivery Business News.
The post Valeritas touts positive results for V-Go wearable insulin delivery device appeared first on MassDevice.